By Elaine Meyer ( December 4, 2009, 5:11 PM EST) -- Biogen Idec Inc. has made a "best and final" tender offer to purchase Facet Biotech Corp., upping its ante from $14.50 to $17.50 a share and urging Facet's stockholders to send a signal to their board by selling their stake in the company....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.